Real-World Patterns of First-Line Treatment Selection After the Introduction of Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
This multicenter retrospective study reveals that in real-world clinical practice following the approval of enfortumab vedotin plus pembrolizumab (EVP) for advanced urothelial carcinoma, treatment selection is primarily driven by patient age and ECOG performance status rather than the structured EV-ineligible criteria (EVITA), with simple clinical variables outperforming composite eligibility tools in predicting non-EVP management.